Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MMP14 | P50281 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | FABP3 | P05413 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9960633 | 0.86 | FABP3 (0.36) | ACHEKDM4EMAPTMAPK1MMP14 | |
| SCHEMBL9960705 | 0.86 | MEN1 (0.33) | ACHEKDM4EMAPTMAPK1MMP14 | |
| SCHEMBL9960838 | 0.85 | TP53 (0.37) | MAPTSMN1; SMN2 | |
| SCHEMBL9960649 | 0.84 | MYC (0.33) | MAPT | |
| SCHEMBL9960813 | 0.76 | MYC (0.44) | KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL9960677 | 0.75 | ELANE (0.34) | KDM4EMAPT | |
| SCHEMBL9960591 | 0.74 | KMT2A (0.33) | MAPTMAPK1FABP3FABP4 | |
| SCHEMBL9960566 | 0.74 | MYC (0.34) | MAPTMAPK1SMN1; SMN2 | |
| SCHEMBL9960762 | 0.73 | ALDH1A1 (0.33) | KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL9960041 | 0.73 | MAPT (0.44) | KDM4EMAPTMAPK1MMP14SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9656945-B2 | 3-acyl-ingenols II | LEO LABORATORIES LIMITED (IE) | 2017-05-23 | — | — | US | claimed |
| US-20130331446-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-12-12 | — | — | US | claimed |
| EP-2655312-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | claimed |
| WO-2012083954-A1 | 3-ACYL-INGENOLS II | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | claimed |
| US-9656945-B2 | 3-acyl-ingenols II | LEO LABORATORIES LIMITED (IE) | 2017-05-23 | — | — | US | disclosed |
| US-20130331446-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-12-12 | — | — | US | disclosed |
| EP-2655312-A1 | 3-ACYL-INGENOLS II | LEO LABORATORIES LIMITED (IE) | 2013-10-30 | — | — | EP | disclosed |
| WO-2012083954-A1 | 3-ACYL-INGENOLS II | LEO PHARMA A/S (DK) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130331446-A1 | 3-ACYL-INGENOLS II | IL33, CXCL8, MMP8 | ACHE 2678/4885KDM4E 4448/4885MAPT 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.